Iferanserin: Completed Phase III enrollment

Ventrus completed enrollment of 604 patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily iferanserin given for 7 or 14 days. Last year, Ventrus acquired all righ...